FHIR IG analytics| Package | hl7.fhir.uv.ebm |
| Resource Type | Evidence |
| Id | Evidence-367934.json |
| FHIR Version | R6 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: Evidence 367934
version: 26; Last updated: 2025-08-18 13:22:42+0000; Language: en
Profile: NonComparativeEvidence
ArtifactPublicationStatus: Active
url: https://fevir.net/resources/Evidence/367934
identifier: FEvIR Object Identifier/367934, FEvIR Linking Identifier/NCT03640312-otherOutcomeMeasure-3--OG001
name: NCT03640312_otherOutcomeMeasure_3_OG001
title: Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312
citeAs:
Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367934. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367934. Computable resource at: https://fevir.net/resources/Evidence/367934#json.
status: Active
author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:
publisher: Computable Publishing LLC
contact: support@computablepublishing.com
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
description:
This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
variableDefinition
description:
Candesartan
note: ,
Outcome Measure Population Description: Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.
Outcome Measure Denominator Units: Participants
variableRole: Population
observed: Patients randomized to the comparison arm took a once daily 8mg candesartan. Candesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks. (Identifier: ClinicalTrials.gov Outcome Measurement Group Id/OG001)
variableDefinition
variableRole: Outcome
observed: Mean Change in Serum Potassium at 12 weeks - (NCT03640312)
statistic
statisticType: mean
quantity: 0.02 mEq/L
SampleSizes
KnownDataCount 30 AttributeEstimates
Type Quantity Standard Deviation 0.31 mEq/L
{
"resourceType": "Evidence",
"id": "367934",
"meta": {
"versionId": "26",
"lastUpdated": "2025-08-18T13:22:42.074Z",
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
]
},
"language": "en",
"text": {
"status": "extensions",
"div": "<!-- snip (see above) -->"
},
"extension": [
{
"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
"valueCodeableConcept": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
"code": "active",
"display": "Active"
}
]
}
}
],
"url": "https://fevir.net/resources/Evidence/367934",
"identifier": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "ACSN",
"display": "Accession ID"
}
],
"text": "FEvIR Object Identifier"
},
"system": "https://fevir.net/FOI",
"value": "367934",
"assigner": {
"display": "Computable Publishing LLC"
}
},
{
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-3--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"name": "NCT03640312_otherOutcomeMeasure_3_OG001",
"title": "Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312",
"citeAs": "Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367934. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367934. Computable resource at: https://fevir.net/resources/Evidence/367934#json.",
"status": "active",
"author": [
{
"name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
}
],
"publisher": "Computable Publishing LLC",
"contact": [
{
"telecom": [
{
"system": "email",
"value": "support@computablepublishing.com"
}
]
}
],
"copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"variableDefinition": [
{
"description": "Candesartan",
"note": [
{
"text": "Outcome Measure Population Description: Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol."
},
{
"text": "Outcome Measure Denominator Units: Participants"
}
],
"variableRole": "population",
"observed": {
"identifier": {
"type": {
"text": "ClinicalTrials.gov Outcome Measurement Group Id"
},
"value": "OG001"
},
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
},
{
"variableRole": "outcome",
"observed": {
"reference": "EvidenceVariable/367899",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcome-3",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Serum Potassium at 12 weeks - (NCT03640312)"
}
}
],
"statistic": [
{
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000573",
"display": "mean"
}
]
},
"quantity": {
"value": 0.02,
"unit": "mEq/L"
},
"sampleSize": {
"knownDataCount": 30
},
"attributeEstimate": [
{
"type": {
"text": "Standard Deviation"
},
"quantity": {
"value": 0.31,
"unit": "mEq/L"
}
}
]
}
]
}